Insulin resistance and risk for stroke

Neurology

Volumn 59, Issue 6, 2002, Pages 809-815

  Kernan, W N ^a   Inzucchi, S E ^a   Viscoli, C M ^a   Brass, L M ^a,b   Bravata, D M ^a,b   Horwitz, R I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; GLYCOGEN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ADULT; BRAIN ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; GERIATRIC PATIENT; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY FUNCTION; LACTIC ACIDOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; STROKE;

EID: 0037167548     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.6.809     Document Type: Review

References (69)

1. Shinozaki K, Naritomi H, Shimizu T, et al. Role of insulin resistance associated with compensatory hyperinsulinemia in ischemic stroke. Stroke 1996;27:37-43.
2. Gertler MM, Leetma HE, Koutrouby RJ, Johnson ED. The assessment of insulin, glucose and lipids in ischemic thrombotic cerebrovascular disease. Stroke 1975;6:77-84.
3. Lindberg O, Tilvis RS, Strandberg TE, et al. Elevated fasting plasma insulin in a general aged population: an innocent companion of cardiovascular diseases. J Am Geriatr Soc 1997;45: 407-412.
4. Wannamethee SG, Perry IJ, Shaper AG. Nonfasting serum glucose and insulin concentrations and the risk of stroke. Stroke 1999;30:1780-1786.
5. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men. The 22 year follow-up results of the Helsinki Policemen Study. Stroke 1998;29:1860-1866.
6. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects, Stroke 1994;25:1157-1164.
7. Lakka H-M, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men. Arch Intern Med 2000;160:1160-1168.
8. Folsom AR, Rasmussen ML, Chambless LE, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care 1999;22: 1077-1083.
9. Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke 2000;31:2936-2941.
10. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-357.
11. Eriksson J, Franssila-Kallunki j, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989;321:337-343.
12. Hollenbeck C, Reaven GM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab 1987;64:1169-1173.
13. Bogardus C, Lillioja S, Howard BV, Reaven G, Mott D. Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects. J Clin Invest 1984;74: 1238-1246.
14. Kernan WN, Viscoli CM, Inzucchi SE, et al. Insulin resistance among patients with ischemic stroke and TIA. Stroke 2002;33: 389.
15. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-176.
16. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334: 374-381.
17. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-706.
18. Corry DB, Tuck MA. Glucose and insulin metabolism in hypertension. Am J Nephrol 1996;16:223-236.
19. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511-2515.
20. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide production. J Clin Invest 1994;94:1172-1179.
21. Defronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975;55:845-855.
22. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 1994;93:2365-2371.
23. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone. Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997;96:4104-4113.
24. Hu R-M, Levin ER, Pedram A, Frank HJL. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993;42:351-358.
25. Reaven GM, Chen Y-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993;92:141-146.
26. van Loon BJP. The cardiovascular risk factor plasminogen activator inhibitor type I is related to insulin resistance. Metabolism 1993;42:945-949.
27. Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998;21:649-654.
28. Trovati M, Anfossi G. Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular. smooth muscle cells. Diabetologia 1998;41:609-622.
29. Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of Insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996;94:2171-2176.
30. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study. JAMA 2000;283:221-228.
31. Association AD. Consensus development conference on insulin resistance. Diabetes Care 1998;21:310-314.
32. Chen W, Srinivasan SR, Elkasabany A, Berenson GS. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (syndrome X) between young parents and their offspring: the Bobalusa Heart Study. Atherosclerosis 1999;145:197-205.
33. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulant, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907.
34. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190-198.
35. Despres J-P, LaMarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-957.
36. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-160.
37. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:121-141.
38. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980;19: 205-210.
39. Perry IJ, Wannamethee G, Whincup PH, Shaper AG, Walker MK, Alberti KGMM. Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 1996;144:224-234.
40. Feskens EJM, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Thromb 1994;14:1641-1647.
41. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 1995;91:831-837.
42. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinaemia is not a major coronary risk factor in elderly men. Diabetologia 1992;35:766-770.
43. Hargreaves AD, Logan RL, Elton RA, Buchanan KD, Oliver MF, Riemersma RA. Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. Atherosclerosis 1992;94:61-69.
44. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 1994;4:40-45.
45. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: The Rancho Bernardo Study, 1984-1991. Am J Epidemiol 1994;140:857-869.
46. Welborn TA, Knuiman MW, Ward N, Whittall DE. Serum insulin is a risk marker for coronary heart disease mortality in men but not in women. Diabetes Res Clin Pract 1994;26: 51-59.
47. Ronnemaa T, Laakso M, Pyorala K, Kallio V, Puuka P. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects. Arterioscler Thromb 1991;11:80-90.
48. Mykkanen L, Laakso M, Pyorala K. High plasma insulin level associated with coronary heart disease in the elderly. Am J Epidemiol 1993;137:1190-1202.
49. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in communities (ARIC) Study. Diabetes Care 1997;20: 935-942.
50. Ruige JB, Assendelft WJJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease. A meta-analysis. Circulation 1998;97:996-1001.
51. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
52. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-2898.
53. Laakso ML, Sarlund H, Salonen R, et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991; 11:1068-1076.
54. Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995;26:956-960.
55. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. Circulation 1996;93:1809-1817.
56. Suzuki M, Shinozaki K, Kanazawa A, et al. Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension 1996;28:593-598.
57. Bonora E, Tessari R, Micciolo R, et al. Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Diabetes Care 1997;20:627-631.
58. Tonino RF. Effect of physical training on the insulin resistance of aging. Am J Physiol 1989;256:E352-E356.
59. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-872.
60. Nolan J, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-1193.
61. Wee CC. Physical activity counseling in primary care. The challenge of effecting behavioral change. JAMA 2001;286:717-719.
62. Schwartz A, Raskin P, Fonseca V, Graveline JF, for the Troglitazone and Exogenous Insulin Study Group. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998;338:861-866.
63. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. Ann Intern Med 1998;128:176-185.
64. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-360.
65. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-2116.
66. Villa E, Rabano A, Albarran OG, Ruilope LM, Garcia-Robles R. Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs. Am J Hypertens 1998;11:844-851.
67. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-1820.
68. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456.
69. Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke. A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001;32:280-299.